AlloSource Announces Two-Year Shelf Life On ProChondrix CR Fresh Cryopreserved Osteochondral Allograft


Centennial, Colo. — March 12, 2019 — AlloSource®, an organization dedicated to advancing the science and use of transplantable allogeneic cells and tissue, today announced that ProChondrix® CR now has a two-year shelf life based on the results of real-time testing. ProChondrix CR helps deliver the…


AlloSource Granted Patent for Proprietary Laser Cutting Enclosure


Centennial, Colo. — November 16, 2018 — AlloSource, an organization dedicated to advancing the science and use of transplantable allogeneic cells and tissue, received U.S. patent 10,105,793, titled Enclosure for laser cutting of human tissue. This patent encompasses AlloSource’s method of producing…


AlloSource Releases AlloFuse Line Extentsion


Company adds AlloFuse Select CM, a cellular allograft matrix, to the AlloFuse portfolio Centennial, Colo. — August 1, 2017 — AlloSource, one of the nation’s largest providers of cartilage, bone, skin, soft-tissue, and cellular allografts to advance patient healing in surgical procedures and wound…


AlloSource’s Burn Skin AlloGraft Rebranded To Pureskin


Company to feature PureSkin at the American Burn Association Annual Meeting Centennial, Colo. — March 20, 2017 — AlloSource, one of the nation’s largest providers of burn skin, cartilage, bone, soft-tissue and cellular allografts for use in surgical procedures and burn and wound care to advance…